Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
86%(6 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_4
1
13%
Ph early_phase_1
1
13%
Ph not_applicable
1
13%
Ph phase_1
2
25%
Ph phase_2
1
13%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (16.7%)
Phase 12 (33.3%)
Phase 21 (16.7%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

completed788%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completed

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
completed

Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers

NCT02348385
terminatedphase_2

Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

NCT03242772
completedphase_1

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

NCT02959892
completedphase_4

Monoamine Contributions to Neurocircuitry in Eating Disorders

NCT02020408
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04132557

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed
NCT02348385

Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers

Completed
NCT03242772Phase 2

Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

Terminated
NCT02959892Phase 1

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

Completed
NCT02020408Phase 4

Monoamine Contributions to Neurocircuitry in Eating Disorders

Completed
NCT01699607Not Applicable

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

Completed
NCT03019822Early Phase 1

Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing

Completed
NCT00733993Phase 1

Caffeine and Cocaine

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8